Copy Link Print Information

Bimagrumab (WT IgG1)

(Synonyms: Anti-ACVR2B Reference Antibody (WT IgG1); BYM338 (WT IgG1))
3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

Bimagrumab (Anti-ACVR2B Reference Antibody) (WT IgG1) is a human monoclonal antibody that retains a native wild-type Fc region and is capable of blocking the activin type II receptor (ActRII). Bimagrumab (WT IgG1) can be used in research concerning pathological muscle loss and weakness..

For research use only. We do not sell to patients.

  • Purity : 99.50%
  • CAS No.: 1356922-05-8
  • Molecular Weight:142.78 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Experimental Validation Results for Bimagrumab (WT IgG1)
  • Bimagrumab (WT IgG1) Chemical Structure
    Bimagrumab (WT IgG1) Chemical Structure
CAS No.: 1356922-05-8
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Bimagrumab (WT IgG1) Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Bimagrumab (WT IgG1)

More
Customer Validation & Images
IFIn Vivo Efficacy StudyWBHistological Imaging/Staining
  • IF
  • In Vivo Efficacy Study
  • WB
  • Histological Imaging/Staining
  • Histological Imaging/Staining

All TGF-β Receptor Isoforms

More

Keywords

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 lambda

  • 1/16

    Immobilized ACVR2B Protein, Human can bind Bimagrumab. The EC50 for this effect is 8.254 ng/mL.

  • 1/16

    Flow cytometric analysis of 106 Jurkat cells with Bimagrumab (HY-P99355, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control.

  • 1/16

    Bimagrumab (WT IgG1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 1;16(1):5976. [Abstract]

    Customer Validation
     Representative microscopy images showing C2C12 myoblast differentiation in the presence of Myostatin, soluble DLK1 + Myostatin, Bimagrumab + Myostatin, or Bimagrumab + soluble DLK1 + Myostatin. Control cells were allowed to differentiate for 72h. Myostatin treatment (4 µg/ml) inhibits C2C12 myoblast differentiation into myotubes as determined by MyoHC staining. Bimagrumab (100 nM) and soluble DLK1 (2 μM) reverse the effect of myostatin on C2C12 differentiation, with no additive effect of adding soluble DLK1 to Bimagrumab treated cells. C2C12 cells were fixed with 4% PFA, immunostained with an anti-MyoHC antibody and an anti-mouse Alexa Fluor 488 secondary antibody. Nuclei were counterstained with Hoechst 33342. Nuclei represented with pseudo color (magenta). The images are representative of one out of two imaging wells per treatment from one experiment. The experiment was independently repeated two times. Scale bar, 100 μm.

  • 1/16

    Bimagrumab (WT IgG1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

    Customer Validation
     Pancreatic tumor samples from chow (n = 6 mice per group) and diabetic (n = 9 mice per group) KPC tumor-bearing mice treated with IgG, bimagrumab, or bimagrumab+metformin. The results showed that two injections of bimagrumab (20 mg/kg, subcutaneously, once weekly) reduced tumor burden in diabetic mice.

  • 1/16

    Bimagrumab (WT IgG1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

    Customer Validation
     Phosphorylated Smad2 levels and total Smad2 expression were detected via western blotting in KPC tumors from the chow and diabetic mice treated with IgG or bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks) (n=3 mice per group).

  • 1/16

    Bimagrumab (WT IgG1) purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 30;16(1):8654. [Abstract]

    Customer Validation
     Representative images of picrosirius red staining (red) in tumors from chow and diabetic KPC tumor-bearing mice treated with IgG or bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks) (n = 6 mice per group).

  • 1/16

    Bimagrumab (WT IgG1) purchased from MedChemExpress. Usage Cited in: Mol Metab. 2024 Feb:80:101880. [Abstract]

    Customer Validation
     Bimagrumab (20 mg/kg, subcutaneous injection, once weekly for two weeks). Representative TA sections stained with H&E (20x magnification, scale bar = 100 um).

  • Bimagrumab (WT IgG1) Chemical Structure
    1/16
  • Bimagrumab (WT IgG1)
  • Immobilized ACVR2B Protein, Human can bind Bimagrumab. The EC50 for this effect is 8.254 ng/mL.
  • Flow cytometric analysis of 106 Jurkat cells with Bimagrumab (HY-P99355, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control.